We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

How much do you need in an ISA to target a £5,555 monthly passive income?

Muhammad Cheema explains how an investor could target £5,555 in monthly passive income over time by making use of a Stocks and Shares ISA.

| More on:
Thoughtful man using his phone while riding on a train and looking through the window

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

As we approach closer to 2026, investors may be looking for new ways to make passive income.

I believe buying shares is one great way to achieve this. This is because investors only need to research the companies they’re invested in, not manage them.

XXX

One tax-efficient way to buy shares for this purpose is to use a Stocks and Shares ISA. You can invest up to £20,000 a year into one, and the dividends received are be tax-free.

Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. Readers are responsible for carrying out their own due diligence and for obtaining professional advice before making any investment decisions.

By investing consistently over time, it’s possible that investors could make a sizeable additional income.

So, how much would you need to aim for £5,555 a month? And what shares may help achieve this?

A plan for passive income

To achieve a passive income of £5,555 a month, investors need to consider high-yielding dividend stocks.

If we target an average portfolio yield of 5%, £1,333,200 would be needed to generate this second income straight away. It’s important to bear in mind that dividends aren’t necessarily guaranteed.

However, I doubt many reading this have that amount of spare cash to use right now. Even if you do, only £20,000 can be invested in an ISA annually to get the benefit of tax-free dividends.

However, it can still be achieved over time. For example, if investors set aside a more reasonable £20,000 initially, and then invest £1,666 a month, they could hit £1,341,746 in 24 years. That’s more than enough to generate £5,555 a month.

Crucially, the £1,666 monthly investment means it’s just under the ISA limit. Moreover, this is computed under some pretty conservative assumptions, notably that annual share price and dividend growth are only 2%. Investors would also need to reinvest their 5% dividends.

A juicy 6.7% yield

As mentioned above, an average yield of 5% could help to generate an investor’s passive income machine. That’s why Pfizer (NYSE:PFE) is a good share to consider, with a handsome 6.7% dividend yield.

Since the start of 2025, the pharmaceutical giant has seen its shares fall by 3.2%. Considering the S&P 500 has gained 16.7% over the same period, this has been disappointing.

However, savvy investors will understand that the cost to obtain the future stream of Pfizer’s dividend is now 3.2% cheaper than it was at the start of the year. Furthermore, its yield is far superior to the S&P 500’s 1.1%.

It also has a strong track record of raising its dividend year on year. It’s now increased every year since 2010.

There are some risks with respect to the company. The biggest is that it has several patents coming to an end over the next few years.

For example, Eliquis, its top-selling medicine, is set to lose its patent exclusivity in Europe in 2026 and in the US in 2028.

However, I still believe the firm’s long-term prospects remain strong. This is because it has plenty of exciting candidates in its pipeline, such as its PF-4044 medicine, which management believes could be used to treat various types of cancer.

While the company may have struggled with growth over the last few years, I believe it has solid foundations to bounce back and resume growth. That’s why I believe investors should consider its shares.

Muhammad Cheema has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

£503 buys 14 shares in this FTSE 250 stock that returned 23.9% annually for the last 15 years

This FTSE 250 stock has averaged a huge return for 15 years. At today's price, £503 buys 14 shares. But…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

£1,000 buys 25 shares in this FTSE 100 stock that’s returned 29.2% annually for the last 10 years

This FTSE 100 mining stock has returned close to 30% a year for a decade. At 3,995p, £1,000 buys 25…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Down 47%, is this growth stock finally worth buying in May?

With a £288m order book and a hidden pipeline of defence and nuclear contracts, is this growth stock now too…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

2 REITs yielding 7%+ to consider for passive income in 2026

A REIT backed by the NHS and another backed by Tesco and Sainsbury's with both yielding 7%+. Here's why I'm…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Just 97 shares of this UK dividend stock generate £238 in passive income

A 5.7% yield, £238 in passive income from just 97 shares, and one of the most divisive dividend stocks on…

Read more »

ISA coins
Investing Articles

£10,000 in an ISA generates a second income of…

The London Stock Exchange is home to some of the world's most generous dividends. But how big a second income…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Expert recommendations: 2 top income stocks yielding 7%+!

With yields of 7.2% and 7.8% respectively, these two income stocks are catching the eyes of institutional analysts. Should investors…

Read more »

Illustration of flames over a black background
Investing Articles

3 top income-focused stocks to buy in May 2026, according to experts

Looking for a stock to buy for income in May 2026? Experts have flagged these three UK dividend shares as…

Read more »